ResearchMoz

Humulin (Type 2 Diabetes) - Analysis and Forecasts to 2020

GlobalData
Published Date » 2012-01-31
No. Of Pages » 44


GlobalDatas pharmaceuticals report, Humulin (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Humulin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Humulin including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Humulin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Humulin in each of the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17
5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19
6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Humulin 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Different Variants of Humulin 25
7.4 Clinical Studies 25
7.4.1 Safety & Efficacy Study in Humalog & Humulin R 25
7.4.2 Safety & Efficacy Study in Lantus & NPH Insulin 26
7.5 Approval History of Humulin 27
7.6 Factors Affecting Sales 27
7.6.1 First in Class 27
7.6.2 Growing Insulin Market 28
7.6.3 Advantage of Insulin Analogs over Humulin 28
7.6.4 Family of Humulin Products 28
7.6.5 Co-Branding Deal with Wal-Mart 28
7.6.6 Availability as OTC 28
7.6.7 No Competition from Biosimilars 28
7.7 Drug Evaluation 29
7.7.1 Drug Risk Benefit Score 29
7.7.2 Intensity of Competition 30
7.8 Sales Estimates 30
7.8.1 Dosing 30
7.8.2 Market Penetration 30
7.8.3 Annual Cost of Therapy 31
7.8.4 Sales Projections of Humulin 32

8 Diabetes Market: Appendix 41
8.1 Market Definitions 41
8.2 List of Abberiviations 41
8.3 Research Methodology 41
8.3.1 Coverage 42
8.3.2 Secondary Research 42
8.3.3 Forecasting 42
8.3.4 Number of patients approved to take the drug 42
8.3.5 Net Penetration of Drug 43
8.3.6 Net Annual Dosing 43
8.3.7 Annual Cost of Therapy 43
8.4 Drug Sales Estimates Model 43
8.5 Contact Us 43
8.6 Disclaimer 44
8.7 Sources 44

List of Tables


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: Type 2 Diabetes Mellitus Adults 26
Table 10: Efficacy and Insulin Dosage in Type 2 Diabetes Mellitus 27
Table 11: Approval of Humulin in the US 27
Table 12: Drug Risk Benefit Score of Humulin R 29
Table 13: Drug Risk Benefit Score of Humulin N 29
Table 14: Humulin R, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 15: Humulin N, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 16: Humulin PreMix, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 17: Humulin Franchise, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 18: Humulin, Type 2 Diabetes, Global, Sales Estimates ($m), 20022020 32
Table 19: Humulin, Type 2 Diabetes, The US, Sales Estimates ($m), 20022020 33
Table 20: Humulin, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022020 34
Table 21: Humulin, Type 2 Diabetes, France, Sales Estimates ($m), 20022020 35
Table 22: Humulin, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022020 36
Table 23: Humulin, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022020 37
Table 24: Humulin, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022020 38
Table 25: Humulin, Type 2 Diabetes, Japan, Sales Estimates ($m), 20022020 39

List of Figures


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylureas 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Branded Market Share By Class (%), 2010 24
Figure 12: Humulin, Type 2 Diabetes, Global, Sales Estimates ($m), 2002-2020 32
Figure 13: Humulin, Type 2 Diabetes, The US, Sales Estimates ($m), 20022020 33
Figure 14: Humulin, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022020 34
Figure 15: Humulin, Type 2 Diabetes, France, Sales Estimates ($m), 20022020 35
Figure 16: Humulin, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022020 36
Figure 17: Humulin, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022020 37
Figure 18: Humulin, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022020 38
Figure 19: Humulin, Type 2 Diabetes, Japan, Sales Estimates ($m), 2002-2020 39
Figure 20: Humulin, Diabetes, Global, Sales Distribution by Country (%), 2020 40
Figure 21: Patients Approved for the Drug 43

Upcoming Reports:

Clinical Trial Management Systems Market - Global Industry Analysis, Size, Growth, Share And Forecast, 2012 - 2018
By - Transparency Market Research
Several studies are performed on a human being to check the efficacy or safety of drugs, devices or therapeutic products, and these types of research performed are known as clinical trials. These researches are carried out before drugs, devices and therapeutic products are launched into the market. They require huge investment at the initial level and in the present scenario it has become mandatory for hospitals to carry out such research. It is expected that the global CTMS (Clinical Trial Management System) market will grow at a CAGR of 14.54% during the period 2011...
Familial Amyloid Polyneuropathy Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy is a genetic disorder caused by the deposition of insoluble amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle. Transthyretin is a transporter of retinol and thyroid hormone; majority of which is made in liver and small amount of the protein is made in brain and eyes. The prevalence of familial amyloid polyneuropathy is very low across the globe. According to a review article published in The Lancet Neurology, although FAP cases has been reported throughout the...
Building Information Modeling (BIM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Building Information Modeling (BIM) enables execution of various processes such as visualization, designing, collaboration and simulation during construction of buildings. Companies in this market offer BIM solutions in software and services models to cater to the specific requirements of their clients. BIM objects maintain digital data required for communication of various project related decisions in construction. With the use of integrated tools, the data stored in BIM can be used to manage the entire lifecycle of a construction project. BIM is used for maintaining data regarding...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

Ford Recalls 65,000 Fusion Models Due to Issues in Ignition Key
Nov 20, 2014  
If anything defines the world of automobiles currently, it would be recalls. It seems that a flood of automobiles has surrounded the global automobiles industry, which once represented a flourishing and highly profitable industry.  The current automobile giants ordering yet another recall is Ford Motors Co. Ford declared on Tuesday that it is recalling nearly 65,000 sedans from...
3D Printed Heart Model for Better Cardiological Treatment
Nov 20, 2014  
According to research carried out by the American Heart Association’s Scientific Sessions 2014, surgeons will be able to treat complex heart disorders in patients, with the help of a three dimensional experimental printed model of the heart. For surgical planning, most cardiac surgeons make use of two dimensional images of the heart taken by MRI, ultrasound, and X-ray. But the problem is...
Los Angeles Auto Show Kicks Off
Nov 20, 2014  
The Los Angeles Auto Show kicked off on Wednesday with a rather upbeat mood. Motoring machines, industry metrics, and hybrid models – the show has lived up to its reputation once more. The Los Angeles Auto Show has begun touring North America from the Los Angeles Convention Center, and the commencement has already had an impact on the market. Gasoline prices dropped under US$3...
Scottish Government to Inject 200 Million Pounds in the Housing Sector
Nov 19, 2014  
The construction and the housing industries of Scotland will get a major financial boost from the Scottish government in terms of additional funding worth 200 million pounds. The main rationale of such a financial boost is to stimulate the housing sector and also safeguarding employment in the construction industry. The housing minister of Scotland has requested the housing leaders to work...
Quarterly Dividend of $0.10 Declared by Tyson Foods, Inc.
Nov 19, 2014  
A quarterly dividend on November 18th was declared by Tyson Foods, reported Analyst Ratings Network.com. The shareholders of the February 27th record will be awarded a dividend of 0.10 per share on March 13th.  This represents a yield of 0.94% and a $0.40 dividend on an annualized basis. However, the ex-dividend date of this particular dividend is February 25th.  Such...